Hypoxia preconditioned plasma: Difference between revisions
Content deleted Content added
rm "term used to describe" per WP:ISAWORDFOR |
m Normalize {{Multiple issues}}: Remove {{Multiple issues}} for only 1 maintenance template(s): Underlinked |
||
| Line 1: | Line 1: | ||
{{Multiple issues| |
|||
{{Underlinked|date=January 2019}} |
{{Underlinked|date=January 2019}} |
||
{{Orphan|date=March 2014}} |
{{Orphan|date=March 2014}} |
||
}} |
|||
[[File:EmaCure Device.jpg|thumb|Image of a prototype bioreactor device for one-step preparation and sampling of Hypoxia Preconditioned Plasma (HPP)]] |
[[File:EmaCure Device.jpg|thumb|Image of a prototype bioreactor device for one-step preparation and sampling of Hypoxia Preconditioned Plasma (HPP)]] |
||
Revision as of 17:30, 31 May 2020
 | This article needs more links to other articles to help integrate it into the encyclopedia. (January 2019) |
Hypoxia preconditioned plasma or hypoxia pre-conditioned plasma (abbreviated as HPP) is the (cell-free) plasma obtained after extracorporeal conditioning (i.e. culturing) of anticoagulated blood under physiological temperature (37 °C) and physiological hypoxia (1–5 %O2). Blood conditioning is typically carried out over 2 to 4 days.
No high quality evidence supports its use for any medical purpose as of 2016.[1]
References
- ^ Steinhoff, Gustav (2016). Regenerative Medicine - from Protocol to Patient: 5. Regenerative Therapies II. Springer. p. 377. ISBN 9783319283869.